[go: up one dir, main page]
Skip to main content
SpringerLink
Log in

Management of Future Outbreak Risks (Prevention, Control and Treatment)

  • Chapter
  • First Online:
Healthcare Informatics for Fighting COVID-19 and Future Epidemics

Part of the book series: EAI/Springer Innovations in Communication and Computing ((EAISICC))

  • 581 Accesses

Abstract

The year 2020 began with the advent of a novel coronavirus identified as SARS-CoV-2, which triggered the coronavirus disease (COVID-19) outbreak globally. It is the third extremely pathogenic and highly contagious coronavirus that has arisen in humans since severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). As it is a respiratory disease that has never been seen before and can spread broadly and rapidly, it gained worldwide attention without the standard of diagnosis and control. The development of therapeutic approaches is essential in preventing future outbreaks and curing infections. In the end, the outbreak could be contained by a reliable vaccine to prevent 2019-nCoV infection, and there’s an immediate need to find initiatives to ensure patients’ health and prevent possible deaths. To prevent and control the next outbreak and pandemic relating to these interfaces, we summarize the existing state of awareness around COVID-19 by addressing prevention steps and monitoring treatment protocols that can help manage both existing and future outbreak risks. Finally, we strongly support for the fastest strategy to develop a vaccine that may be immune towards any new mutations which this virus could trigger in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. J. Yang, Y. Zheng, X. Gou, K. Pu, Z. Chen, Q. Guo, R. Ji, H. Wang, Y. Wang, Y. Zhou, Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: A systematic review and meta-analysis. Int. J. Infect. Dis. 94, 91–95 (2020)

    Article  Google Scholar 

  2. A.R. Sahin, 2019 Novel coronavirus (COVID-19) outbreak: A review of the current literature. Eurasian J. Med. Investig. 4, 1–7 (2020)

    Google Scholar 

  3. J.S. Guy, Turkey coronavirus is more closely related to avian infectious bronchitis virus than to mammalian coronaviruses: A review. Avian Pathol. 29, 207–212 (2000)

    Article  Google Scholar 

  4. F. Patrucco, F. Gavelli, R. Shi, N. De Vita, A. Pavot, L.M. Castello, P. Ravanini, P.E. Balbo, Coronavirus disease 2019 outbreak. Panminerva Med. 62(2), 73–74 (2020)

    Article  Google Scholar 

  5. H. Laude, K. Van Reeth, M. Pensaert, Porcine respiratory coronavirus: Molecular features and virus-host interactions. Vet. Res. 24, 125–150 (1993)

    Google Scholar 

  6. S.L. Sawicki, S.G. Siddell, Comparative perception of COVID-19 transcript. J. Virol. 81, 20–29 (2007)

    Article  Google Scholar 

  7. D. Cavanagh, Coronavirus avian infectious bronchitis virus. Vet. Res. 38, 281–297 (2007)

    Article  Google Scholar 

  8. J. Pang, M.X. Wang, I.Y.H. Ang, et al., Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): A systematic review. J. Clin. Med. 9, 623 (2020)

    Article  Google Scholar 

  9. S.R. Weiss, S. Navas-Martin, Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol. Mol. Biol. Rev. 69, 635–664 (2005)

    Article  Google Scholar 

  10. E.J. Snijder, M.C. Horzinek, Toroviruses: Replication, evolution and comparison with other members of the coronavirus-like superfamily. J. Gen. Virol. 74, 2305–2316 (1993)

    Article  Google Scholar 

  11. J.M.A. Van Den Brand, S.L. Smits, B.L. Haagmans, Pathogenesis of Middle East respiratory syndrome coronavirus. J. Pathol. 235, 175–184 (2015)

    Article  Google Scholar 

  12. C.C. Bergmann, T.E. Lane, S.A. Stohlman, Coronavirus infection of the central nervous system: Host-virus stand-off. Nat. Rev. Microbiol. 4, 121–132 (2006)

    Article  Google Scholar 

  13. L. Zhang, Y. Liu, Potential interventions for novel coronavirus in China: A systematic review. J. Med. Virol. 92, 479–490 (2020)

    Article  Google Scholar 

  14. M.M.C. Lai, Of genome. Policy Anal. 04, 33–36 (2000)

    Google Scholar 

  15. S. Perlman, Review of pathological and immunological aspects. Adv. Exp. Med. Biol. 440, 503–513 (1998)

    Article  Google Scholar 

  16. P. Spychalski, A. Błażyńska-Spychalska, J. Kobiela, Estimating case fatality rates of COVID-19. Lancet Infect. Dis. 20, 774–775 (2020)

    Article  Google Scholar 

  17. J. Phua, L. Weng, L. Ling, M. Egi, C. Lim, J.V. Divatia, B.R. Shrestha, Y.M. Arabi, J. Ng, Review Intensive care management of coronavirus disease 2019 (COVID-19): Challenges and recommendations. Lancet Respir. 2019, 1–12 (2020)

    Google Scholar 

  18. A. Cortegiani, G. Ingoglia, M. Ippolito, A. Giarratano, S. Einav, A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J. Crit. Care 57, 279–283 (2020)

    Article  Google Scholar 

  19. T. Singhal, A review of coronavirus disease-2019 (COVID-19). Indian J. Pediatr. 87, 281–286 (2020)

    Article  Google Scholar 

  20. D.M.G. Halpin, R. Faner, O. Sibila, J.R. Badia, A. Agusti, Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir. Med. 8, 436–438 (2020)

    Article  Google Scholar 

  21. J. Yazdany, A.H.J. Kim, Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: What every clinician should know. Ann. Intern. Med. 172(11), 754–755 (2020)

    Article  Google Scholar 

  22. A. Murphy, Z. Abdi, I. Harirchi, M. Mckee, E. Ahmadnezhad, Correspondence and Iran’s capacity to. Lancet Public Health 2667, 30083 (2020)

    Google Scholar 

  23. X.H. Jin, K.I. Zheng, K.H. Pan, Y.P. Xie, M.H. Zheng, COVID-19 in a patient with chronic lymphocytic leukaemia. The Lancet Haematology 7(4), e351–e352 (2020)

    Article  Google Scholar 

  24. B. Owens, Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology. Lancet Rheumatol. 9913, 30089 (2020)

    Google Scholar 

  25. X. Yao, F. Ye, M. Zhang, et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome main point: Hydroxychloroquine was found to be more potent than chloroquine at inhibiting SARS-CoV-2 in vitro. Clin. Infect. Dis. 2, 1–25 (2020)

    Google Scholar 

  26. C. Vardavas, K. Nikitara, COVID-19 and smoking: A systematic review of the evidence. Tob. Induc. Dis. 18, 1–4 (2020)

    Article  Google Scholar 

  27. D. Zhou, S.-M. Dai, Q. Tong, COVID-19: A recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J. Antimicrob. Chemother. 75(7), 1667–1670 (2020)

    Article  Google Scholar 

  28. C. Sohrabi, Z. Alsafi, N.O. Neill, M. Khan, A. Kerwan, Since January 2020 Elsevier has created a COVID-19 resource Centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource Centre is hosted on Elsevier Connect, the company’s public news and information (2020)

    Google Scholar 

  29. J. Liu, R. Cao, M. Xu, X. Wang, H. Zhang, H. Hu, Y. Li, Z. Hu, W. Zhong, M. Wang, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 6, 6–9 (2020)

    Article  Google Scholar 

  30. S.A. Rasmussen, J.C. Smulian, J.A. Lednicky, T.S. Wen, D.J. Jamieson, Coronavirus disease 2019 (COVID-19) and pregnancy: What obstetricians need to know. Am. J. Obstet. Gynecol. (2020). https://doi.org/10.1016/j.ajog.2020.02.017

  31. O. Mitjà, B. Clotet, Use of antiviral drugs to reduce COVID-19 transmission. Lancet Glob. Health 8(5), e639–e640 (2020)

    Article  Google Scholar 

  32. R. Viner, S. Russell, H. Croker, J. Packer, J. Ward, C. Stansfield, O. Mytton, R. Booy, School closure and management practices during coronavirus outbreaks including COVID-19: A rapid narrative systematic review. SSRN Electron. J. 2019, 1–8 (2020)

    Google Scholar 

  33. H. Wang, T. Li, P. Barbarino, et al., Dementia care during COVID-19. Lancet 6736, 19–20 (2020)

    Google Scholar 

  34. R. Verity, L.C. Okell, I. Dorigatti, et al., Estimates of the severity of coronavirus disease 2019: A model-based analysis. Lancet Infect. Dis. 3099, 1–9 (2020)

    Google Scholar 

  35. P.M. De Salazar, A.R. Taylor, Article used experimental data to measure the bias of visitor-derived COVID-19 prevalence rate in Wuhan, China. Lancet Infect. Dis. 3099, 1–6 (2020)

    Google Scholar 

  36. W. Zhang, Y. Zhao, F. Zhang, Q. Wang, T. Li, Z. Liu, The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China. Clin. Immunol. 214, 108393 (2020)

    Article  Google Scholar 

  37. H. Topic, Can Chinese medicine be used for prevention of Corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin. J. Integr. Med. 26, 243–250 (2020)

    Article  Google Scholar 

  38. Y. Yang, S. Islam, J. Wang, Y. Li, X. Chen, Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): A review and perspective. Int. J. Biol. Sci. (2020). https://doi.org/10.7150/ijbs.45538

  39. Y. Yan, W.I. Shin, Y.X. Pang, Y. Meng, J. Lai, C. You, The first 75 days of novel coronavirus (SARS-CoV-2) outbreak: Recent advances. Prev. Treat 17(7), 2323 (2020)

    Google Scholar 

  40. D.M. Roden, R.A. Harrington, Considerations for drug interactions on QTc in exploratory COVID-19 treatment. Circulation 141(24), e906–e907 (2020)

    Article  Google Scholar 

  41. H. Fan, L. Wang, W. Liu, X. An, Z. Liu, X. He, L. Song, Y. Tong, Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model. Chin. Med. J. 133, 1051–1056 (2020)

    Article  Google Scholar 

  42. H. Zhu, N. Sze, A. Mak, Y. Yan, Y. Zhu, Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID - 19. J. Med. Virol. 92(7), 740–746 (2020)

    Article  Google Scholar 

  43. T. Tian, Y. Doctor, J. Dan, Q. Doctor, W. Yan, Z. Doctor, Y. Wang, A. Gui, Q. Wang, A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease-19 treatment option. J. Med. Virol. 92, 556–563 (2020)

    Article  Google Scholar 

  44. J. Storz, R. Rott, G. Kaluza, Enhancement of plaque formation and cell fusion of an enteropathogenic coronavirus by trypsin treatment. Infect. Immun. 31, 1214–1222 (1981)

    Article  Google Scholar 

  45. C. Sargiacomo, F. Sotgia, M.P. Lisanti, COVID-19 and chronological aging: Senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Aging 12, 6511–6517 (2020)

    Article  Google Scholar 

  46. L. Yang, Y. Ren, Moral obligation, public leadership, and collective action for epidemic prevention and control: Evidence from the corona virus disease 2019 (COVID-19) emergency. Int. J. Environ. Res. Public Health 17(8), 2731 (2020)

    Article  MathSciNet  Google Scholar 

  47. Z. Wang, X. Chen, Y. Lu, F. Chen, W. Zhang, Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 14(1), 64–68 (2020)

    Article  Google Scholar 

  48. X. Yao et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus. Clin. Infect. Dis. 71, 732–739 (2020)

    Article  Google Scholar 

  49. H.B. Harmful, Clinical infectious diseases, 2019–2020 (2020)

    Google Scholar 

  50. J. Wu, W. Li, X. Shi, et al., Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J. Intern. Med. 288(1), 128–138 (2020)

    Article  Google Scholar 

  51. A.H. De Wilde, V.S. Raj, D. Oudshoorn, et al., MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-a treatment. J. Gen. Virol. 94(Pt 8), 1749–1760 (2013)

    Article  Google Scholar 

  52. Z. Min, C. Jun, F. Fu, et al., Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J. Pediatr. 16, 240–246 (2020)

    Article  Google Scholar 

  53. F. Violi, D. Pastori, R. Cangemi, P. Pignatelli, L. Loffredo, Hypercoagulation and antithrombotic treatment in coronavirus 2019: A new challenge. Thromb. Haemost. 120(6), 949–956 (2020)

    Article  Google Scholar 

  54. M.R. Basiri, Treatments and morbidity prevention of Covid-19. J. Pharm. Pharmacol. 8, 89–90 (2020)

    MathSciNet  Google Scholar 

  55. J. Dyall, C.M. Coleman, B.J. Hart, et al., Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob. Agents Chemother. 58, 4885–4893 (2014)

    Article  Google Scholar 

  56. B.S. Chhikara, B. Rathi, J. Singh, Corona virus SARS-CoV-2 disease COVID-19: Infection, prevention and clinical advances of the prospective chemical drug therapeutics. Chem. Biol. Lett. 7, 63–72 (2020)

    Google Scholar 

  57. A.K. Panda, S. Kar, A.K. Dixit, Ayurveda consensus develop strategies for prevention of COVID-19. J. Ayurveda Integr. Med. Sci. 5(1), 96–107 (2020)

    Google Scholar 

  58. S. White, M. Omer, G.N. Mohamma, International knowledge, attitude and practice on prevention of airborne and droplet infections during the outbreak of corona virus among the college students in University of Bisha, Saudi Arabia, Reviewed By Introduction. Med. Sci. 11, 20773–20776 (2020)

    Google Scholar 

  59. J.F. Burke, Letter: The coronavirus disease 2019 global pandemic: A neurosurgical treatment algorithm. Neurosurgery 87, E50–E57 (2020)

    Article  Google Scholar 

  60. H. Lu, Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci. Trends 14, 69–71 (2020)

    Article  Google Scholar 

  61. Z. Yang, J. Liu, Y. Zhou, X. Zhao, Q. Zhao, J. Liu, The effect of corticosteroid treatment on patients with coronavirus infection: A systematic review and meta-analysis. J. Infect. 81, 13–20 (2020)

    Article  Google Scholar 

  62. B.D. Vakser, O.P. Pishchulina, Prevention of marginal corona discharges in the insulation of high-voltage electric machines. Russ. Electr. Eng. 80, 136–138 (2009)

    Article  Google Scholar 

  63. L. Zha, S. Li, L. Pan, B. Tefsen, Y. Li, N. French, L. Chen, G. Yang, E.V. Villanueva, Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med. J. Aust. (2020). https://doi.org/10.5694/mja2.50577

  64. D. Vauzour, A. Rodriguez-mateos, G. Corona, M.J. Oruna-concha, J.P.E. Spencer, Mechanisms of action. Nutrients 2(11), 1106–1131 (2010)

    Article  Google Scholar 

  65. K.L. Shen, Y.H. Yang, Diagnosis and treatment of 2019 novel coronavirus infection in children: A pressing issue. World J. Pediatr. 16, 219–221 (2020)

    Article  Google Scholar 

  66. S.A. Baron, C. Devaux, P. Colson, Teicoplanin: An alternative drug for the treatment of coronavirus COVID-19? Int. J. Antimicrob. Agents 55, 105944 (2020)

    Article  Google Scholar 

  67. End-winding CING, Jf/ ‘fa/$77 5. 106273017, 16–18 (1948)

    Google Scholar 

  68. H. Liang, G. Acharya, Novel corona virus disease (COVID-19) in pregnancy: What clinical recommendations to follow? Acta. Obstet. Gynecol. Scand. 99, 439–442 (2020)

    Article  Google Scholar 

  69. N. Tang, H. Bai, X. Chen, J. Gong, D. Li, Z. Sun, Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 18, 1094–1099 (2020)

    Article  Google Scholar 

  70. K. Shen, Y. Yang, T. Wang, D. Zhao, Y. Jiang, R. Jin, Y. Zheng, Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: Experts’ consensus statement. World J. Pediatr. 16, 223–231 (2020)

    Article  Google Scholar 

  71. M. Kawase, K. Shirato, L. Van Der Hoek, F. Taguchi, S. Matsuyama, Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J. Virol. 86, 6537–6545 (2012)

    Article  Google Scholar 

  72. N. Lee, K.C.A. Chan, D.S. Hui, et al., Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information. (2020). https://doi.org/10.1016/j.jcv.2004.07.006

Download references

Author information

Authors and Affiliations

  1. Department of Chemistry, Faculty of Technology and Sciences, Lovely Professional University, Phagwara, Punjab, India

    Abhinay Thakur & Ashish Kumar

Authors
  1. Abhinay Thakur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ashish Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Information and Communication Technology, University of Malta, Msida, Malta

    Lalit Garg

  2. Electronics & Communication Engineering, Birla Institute of Technology, Jharkhand, India

    Chinmay Chakraborty

  3. University of Mons, Mons, Belgium

    Saïd Mahmoudi

  4. Harrisburg University of Science and Tec, Harrisburg, PA, USA

    Victor S. Sohmen

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Thakur, A., Kumar, A. (2022). Management of Future Outbreak Risks (Prevention, Control and Treatment). In: Garg, L., Chakraborty, C., Mahmoudi, S., Sohmen, V.S. (eds) Healthcare Informatics for Fighting COVID-19 and Future Epidemics. EAI/Springer Innovations in Communication and Computing. Springer, Cham. https://doi.org/10.1007/978-3-030-72752-9_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-72752-9_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-72751-2

  • Online ISBN: 978-3-030-72752-9

  • eBook Packages: EngineeringEngineering (R0)

Publish with us

Policies and ethics

Search

Navigation